Unknown

Dataset Information

0

Therapeutic strategies for acute intermittent porphyria.


ABSTRACT: Acute intermittent porphyria (AIP) is an autosomal dominant disease caused by mutations in porphobilinogen deaminase (PBGD), the third enzyme of the heme synthesis pathway. Symptoms of AIP usually manifest as intermittent acute attacks with occasional neuropsychiatric crises. The management of AIP includes treatment of acute attacks, prevention of attacks, long-term monitoring and treatment of chronic complications. Intravenous injection of heme is the most effective method of treating acute attacks. Carbohydrate loading is used when heme is unavailable or in the event of mild attacks. Symptomatic treatment is also needed during attacks. Prevention of attacks includes eliminating precipitating factors, heme prophylaxis and liver transplantation. New treatment options include givosiran (siRNA) to down-regulate ALA synthase-1 (ALAS1) and the messenger RNA of PBGD (PBGD mRNA) delivered to the liver cells of patients with AIP. Long-term monitoring of chronic complications includes regular liver-kidney function and hepatocellular carcinoma (HCC) screening.

SUBMITTER: Zhao L 

PROVIDER: S-EPMC7586882 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4607616 | BioStudies
2012-01-01 | S-EPMC3295788 | BioStudies
2013-01-01 | S-EPMC3687345 | BioStudies
2011-01-01 | S-EPMC3034840 | BioStudies
2014-01-01 | S-EPMC4040563 | BioStudies
2015-01-01 | S-EPMC4877445 | BioStudies
2021-01-01 | S-EPMC7907807 | BioStudies
2016-01-01 | S-EPMC5059188 | BioStudies
2019-01-01 | S-EPMC6612539 | BioStudies
2018-01-01 | S-EPMC6133185 | BioStudies